Cargando…
Case Report: Exacerbation of varices following atezolizumab plus bevacizumab treatment of hepatocellular carcinoma: A case series and literature review
Recently, a combined regimen of atezolizumab and bevacizumab (AB) treatment has been approved as a first-line treatment in patients with advanced hepatocellular carcinoma (HCC), contributing to prolonged survival. However, we often encounter cases where treatment must be discontinued due to the occu...
Autores principales: | Suzuki, Hiroyuki, Iwamoto, Hideki, Shimose, Shigeo, Niizeki, Takashi, Shirono, Tomotake, Noda, Yu, Kamachi, Naoki, Yamaguchi, Taizo, Nakano, Masahito, Kuromatsu, Ryoko, Koga, Hironori, Kawaguchi, Takumi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9355247/ https://www.ncbi.nlm.nih.gov/pubmed/35936693 http://dx.doi.org/10.3389/fonc.2022.948293 |
Ejemplares similares
-
Association between Adverse Events and Prognosis in Patients with Hepatocellular Carcinoma Treated with Atezolizumab Plus Bevacizumab: A Multicenter Retrospective Study
por: Shimose, Shigeo, et al.
Publicado: (2022) -
Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice
por: Iwamoto, Hideki, et al.
Publicado: (2021) -
The impact of curative conversion therapy aimed at a cancer‐free state in patients with hepatocellular carcinoma treated with atezolizumab plus bevacizumab
por: Shimose, Shigeo, et al.
Publicado: (2023) -
Primary Treatment with Molecular‐Targeted Agents for Hepatocellular Carcinoma: A Propensity Score‐matching Analysis
por: Nakano, Masahito, et al.
Publicado: (2020) -
Evaluating the therapeutic effect of lenvatinib against advanced hepatocellular carcinoma by measuring blood flow changes using contrast‐enhanced ultrasound
por: Kamachi, Naoki, et al.
Publicado: (2021)